Name: Latest research reports of Aurobindo Pharma Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Aurobindo Pharma Ltd.
Rating: 5
Author: Motilal Oswal

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804 | ISIN: INE406A01037 | Industry: Pharmaceuticals
| Mid-range Performer

1571.7000 -39.20 (-2.43%)

NSE Oct 23, 2026 15:31 PM

45.51% Gain from 52W Low

Volume: 650.6K

Aurobindo Pharma Ltd.

06 Aug 2026

1571.70

-2.43%

Operational delivery remains on track

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

Aurobindo Pharma (ARBP) delivered in-line revenue in 1QFY27. It delivered better-than-expected EBITDA/PAT (6%/8% beat) for the quarter.

Aurobindo Pharma Ltd. is trading below its 30 day SMA of 1675.0